Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 77-84 , March 2005

Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine

  • Otilia M. Koo, MD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
    • ,
  • Israel Rubinstein, MD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
    • Department of Medicine, University of Illinois, Chicago, Illinois
    • Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois
    • ,
  • Hayat Onyuksel, PhD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
    • Department of Bioengineering, University of Illinois, Chicago, Illinois
    • Corresponding Author InformationCorresponding author. University of Illinois at Chicago, College of Pharmacy, Department of Biopharmaceutical Sciences (M/C 865), 833 South Wood St, Chicago, IL 60612-7231.

Received 24 September 2004 ,Accepted 18 November 2004.

References 

  1. Clements MK, Wasi S, Daoud SS. Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro. Anticancer Drugs. 1996;7:851–857
  2. Natelson EA, Giovanella BC, Verschragen CF, Fehir KM, De Ipolyi PD, Harris N, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann. N. Y. Acad. Sci. 1996;803:224–230
  3. Gupta M, et al. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 1997;3:1653–1660
  4. Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. J. Nat. Products. 2004;67:129–135
  5. Redinbo MR, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998;279:1504–1513
  6. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002;8:641–661
  7. Kehrer DF, et al. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs. 2001;12:89–105
  8. Burke TG, et al. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 1993;32:5352–5364
  9. Schaeppi U, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC-100880). Cancer Chemother. Rep 3. 1974;5:25–36
  10. Erickson-Miller CL, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother. Pharmacol. 1997;39:467–472
  11. Ashok B, et al. In vitro characterization of pegylated phospholipid micelles for improved drug solubilization: effects of peg chain length and PC incorporation. J. Pharm. Sci. 2004;93:2476–2487
  12. Krishnadas A, Rubinstein I, Onyuksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm. Res. 2003;20:297–302
  13. Onyuksel H, et al. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 1999;16:155–160
  14. Working PK, Dayan AD. Pharmacological-toxicological expert report—CAELYX (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 1996;15:751–785
  15. Allen C, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. 2002;22:225–250
  16. Maeda H, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003;3:319–328
  17. Cortesi R, et al. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm. 1997;159:95–103
  18. Ertl B, et al. Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J. Control Release. 1999;61:305–317
  19. Skehan P, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990;82:1107–1112
  20. Papazisis KT, et al. Optimization of the sulforhodamine B colorimetric assay. J. Immunol. Methods. 1997;208:151–158
  21. Johnson RE, Kirchhoff CF, Gaud HT. Mannitol-sucrose mixtures — versatile formulations for protein lyophilization. J. Pharmaceutical Sci. 2002;91:914–922
  22. Onyuksel H, et al. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides. 2003;24:281–286
  23. Zhang L, et al. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J. Control. Release. 2004;96:135–148
  24. Nabiev I, et al. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem. Pharmacol. 1998;55:1163–1174
  25. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discovery. 2004;3:785–796
  26. Barreiro-Iglesias R, et al. Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J. Control Release. 2004;97:537–549
  27. Mukerjee P, Mysels KJ. In: Critical Micelle Concentrations of Aqueous Surfactant Systems. vol. 36:Washington (DC): US National Bureau of Standards; 1971;
  28. Sethi V. Delivery of phospholipid-associated VIP for the effective treatment of rheumatoid arthritis. [dissertation] In: Chicago: University of Illinois; 2003;p. 81–85
  29. Daoud SS, Fetouh MI, Giovanella BC. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs. 1995;6:83–93
  30. Tsukioka Y, et al. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn. J. Cancer Res. 2002;93:1145–1153
  31. Campbell RB, Balasubramanian SV, Straubinger RM. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharmaceutical Sci. 2001;90:1091–1105
  32. Zhao L, Feng SS, Go ML. Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J. Pharmaceutical Sci. 2004;93:86–98
  33. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002;54:235–252
  34. Bernsdorff C, Reszka R, Winter R. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J. Biomed. Mater. Res. 1999;46:141–149
  35. Mi Y, et al. Effects of polyethylene glycol molecular weight and concentration on lactate dehydrogenase activity in solution and after freeze-thawing. PDA J. Pharm. Sci. Technol. 2002;56:115–123
  36. Heller MC, Carpenter JF, Randolph TW. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J. Pharmaceutical Sci. 1999;88:58–64

PII: S1549-9634(04)00003-6

doi: 10.1016/j.nano.2004.11.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 77-84 , March 2005

Article Tools

* Image Usage & Resolution